August 2014 August 2014
New Products - Mabthera SC
Mabthera SC (rituximab (rch)) is a genetically engineered chimeric murine/ human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. Mabthera SC is indicated for treatment of patients with: CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkin’s lymphoma, CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma and CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma, in combination with chemotherapy. It is available as a single use vial containing a solution for subcutaneous injection (1400 mg/11.7 mL) in packs of 1’s.